Bausch + Lomb to Advance Eye Disease Treatment Following FDA Meeting
By Elias Schisgall
Bausch + Lomb said it plans to advance one of its eye disease treatments following a meeting with the Food and Drug Administration it described as constructive.
The eye health company said the FDA meeting gave clarity on the development path of BL1243, or tonabersat, a treatment of dry age-related macular degeneration.
The FDA was supportive in principle of a proposed initial study design, the company said, adding that results from the initial study are expected to support advancement into a phase 2 study. The clinical program in dry AMD is expected to launch in 2027.
"The oral route of administration, prior clinical experience and potential application in earlier-stage disease make BL1243 a particularly compelling program as we continue building the next generation of treatments for eye health," Chief Medical Officer Yehia Hashad said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
October 06, 2026 17:06 ET (21:06 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
3 Stocks to Sell and 3 Stocks to Buy for October
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
United States